ANTI-AGING EFFICACY AND SAFETY OF GLYCOSIDES-BASED STANDARDIZED FENUGREEK SEED EXTRACT SUPPLEMENTATION IN HEALTHY AGING ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Objective: The efficacy and safety evaluation of oral “glycosides-based standardized fenugreek seed extract" (SFSE-G) supplementation to a healthy aging adult population. Methods: A total of 112 healthy individuals aged ≥ 45 years (determined by chronological age and Levine’s phenotypic age) were randomized using a computer-generated list (1:1 ratio) to receive 300 mg capsules of either SFSE-G or placebo daily for 12 weeks in a double-blind design. The outcome measures were changes in plasma “nicotinamide adenine dinucleotide” (NAD⁺) levels, plasma “adenosine triphosphate” (ATP) levels, phenotypic age, physical performance, fatigue, and quality of life, along with safety and tolerability. Results: Out of 112 participants enrolled, 103 completed the study (SFSE-G: 50; placebo: 53). Plasma NAD+ concentrations were significantly (P < 0.05) higher when age correlated in SFSE-G-treated groups (vs. placebo). No serious adverse events or safety concerns were reported, indicating good tolerability of treatments. In addition, the study found that 12 weeks of 300 mg SFSE-G oral supplementation significantly (P < 0.05) increased ATP levels, improved physical fatigue, and showed trends in reducing phenotypic age and improving quality of life in correlation with age. Conclusion: SFSE-G supplementation showed potential to mitigate age-related declines in energy metabolism and physical fatigue, with a robust safety profile.